Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800696 | 1.00 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL13253090 | 0.87 | TDP1 (0.47) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL23710652 | 0.87 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL805047 | 0.87 | POLB (0.46) | POLBMEN1USP2KMT2ATDP1 | |
| SCHEMBL25504886 | 0.85 | MEN1 (0.51) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL25504874 | 0.85 | MEN1 (0.51) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL25504929 | 0.85 | MEN1 (0.51) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL12404717 | 0.85 | SLC28A1 (0.53) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL16904879 | 0.85 | MEN1 (0.51) | POLBMEN1USP2KMT2AP2RY2 | |
| SCHEMBL12404716 | 0.85 | MEN1 (0.51) | POLBMEN1USP2KMT2AP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | POLB 119/4885MEN1 1646/4885USP2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.